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Thus far, no role has been established for the
enzyme amylase in the intermediate carbohydrate
metabolism. The recent work of Cori and co-
workers (1, 2), and of Ostern, Herbert, and
Holmes (3), makes it appear highly improbable
that amylase participates in the carbohydrate
metabolism of liver, muscle, and other tissues.
A previous communication (4) reported enzyme
studies on the liver tissue in glycogen-storage dis-
ease (von Gierke's disease), which failed to
demonstrate any definite abnormality in liver
amylase activity in this disease of carbohydrate
metabolism. Nevertheless, abnormal blood amy-
lase activity has often been reported in the com-
mon diseases of carbohydrate metabolism-dia-
betes and liver disease. In fact, only a single
report (Norby (5)) recording no alteration in
the enzyme activity in diabetes is encountered.
However, among the numerous other reports,
there is marked divergence of opinion concerning
the nature of the abnormality in amylase activity.
Almost as many papers are found favoring an
increase in blood amylolytic activity in these con-
ditions as there are reporting the opposite, and in-
deed, experimental work is often presented to
corroborate the findings, whether they be high or
low (6).
These circumstances prompted a reinvestigation
of blood amylase activity, with a revised method,
in patients suffering from diabetes, hepato-cellular
and other kinds of liver disease, and in a patient
with glycogen-storage disease. In order to obtain
a basis for comparison, similar determinations
were carried out in a series of normal subjects
and also in several children suffering from various
1 Work aided by a grant from the Rockefeller Founda-
tion, the Bingham Associates Fund, and the Chariton
Fund.
2Work completed during tenure of Emanuel Libman
Fellowship.
childhood diseases which do not affect the carbo-
hydrate metabolism.
In sharp contrast with the divergent reports on
blood amylase activity in disturbances of carbo-
hydrate metabolism is the marked agreement of
results recorded in acute disease involving the
excretory function of the pancreas. Schlesinger
(7), in 1908, demonstrated that ligation of the
pancreatic ducts in animals produced increased
blood amylase activity. Since that time, aug-
mented blood amylase activity has been shown, by
numerous authors, to bear a definite clinical and
experimental relationship to this type of pan-
creatic disease, as is pointed out in recent articles
(8, 9). It was, therefore, considered advisable
also to determine the blood amylase activity in
this disease category with the revised method.
The basis for an entirely reliable method for
the determination of blood amylase activity lies in
the following facts: (1) The hydrolysis of starch
to reducing sugars by amylase takes place as a
monomolecular reaction during a certain phase of
the splitting (10, 11) ; and (2) these sugars,
chiefly maltose, can be measured with a high de-
gree of accuracy. A method was devised which
includes fractional splitting as an integral part of
the procedure, thereby assuring measurement of
the hydrolysis during its monomolecular phase.
Hanes' (12) modification of the Hagedorn-Jensen
method was employed to estimate the reducing
sugars formed, since this method yields accurate
results for such sugars in the presence of starch.
The amylase method, therefore, is based on the
saccharifying power of the enzyme. This basis
of measuring amylolytic activity was first popu-
larized by Kjeldahl 8 in 1880. Since that time the
saccharification method has been employed in
modified form by many authors including Sher-
man et al. (10), Willstiitter et al. (11), Somogyi
3 Quoted by Sherman et al. (10).
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(13), and others. The method described in this
paper offers the advantage derived from the frac-
tional splitting which is incorporated. This makes
it possible to ascertain in each instance whether
or not the determination was made during the
monomolecular phase of amylolysis.
METHOD
There are three parts: I. The enzymatic hydrolysis of
starch; II. deproteinization of serum proteins; III. deter-
mination of the reducing substances formed. Interruption
may be made between any of the parts.
The reagents used are as follows: Substrate, 1.4 per
cent water clear solution of soluble starch (Kalbaum-
Zulkowsky); M/15 Na2HPO4and KH,PO4 buffer having
a pH of 6.8; activator, M/5 NaCl; IN HCl and NaOH;
10 per cent neutral sodium tungstate4; and the reagents
for the Hanes' method.
Part I. Place 25 cc. of substrate, 15 cc. of buffer, 5 cc.
of activator, and 2.5 cc. of distilled water in a 125 cc.
Erlenmyer flask. The latter is immersed in a thermo-
statically controlled waterbath, kept at 370 C. for the
duration of the hydrolysis. When the temperature of the
contents of the flask reaches 370 C., 2.5 cc. of serum are
added with continuous shaking, and immediately there-
after 10 cc. of the flask's contents are transferred to a
15 cc. centrifuge tube containing 1 cc. of IN HCI (the
HCI inactivates the enzyme and also facilitates the pre-
cipitation of the proteins in Part II). The time is noted.
Three subsequent 10 cc. samples are similarly treated at
exactly 20, 40, and 60 minutes later. Thus, 4 aliquot
fractions are obtained, each containing 0.5 cc. of serum.
The first fraction removed serves as the blank.
Part 1I. Deproteinization is accomplished by adding
2 cc. of the sodium tungstate to each fraction, stirring,
and centrifuging for 5 minutes. The water clear super-
natant fluid is decanted into 50 cc. Hagedorn-Jensen tubes,
each of which contains 1 cc. of 1N NaOHto neutralize
the HCI used in Part I.
Part III. The amount of reducing substance in each
fraction is measured by the Hanes' method.
The method of calculating the amylolytic activity and
several examples to illustrate the findings in normal hu-
man serum are given in Tables I and II. The average
20-minute sodium thiosulfate titration value is multiplied
by 2, to obtain the value for 1 cc. of serum, and by the
conversion factor for maltose (0.55). The product thus
obtained is multiplied by 3 to obtain the amount split in
1 hour (i.e., the measure of the amylolytic activity of the
serum).
It will be seen from Tables I and II that a straight line
type of curve is obtained if the amount of reducing sub-
stance found in the fractions is plotted against the time
elapsed.
4 Since the samples must be neutral before Part III is
carried out, the iN HC1 and the NaOHmust be made up




N/75 Na2SsO3 titration values of the fractions
Subject
Blank 20 minutes 40 minutes 60 minutes
A 7.07 6.07 5.08 4.05
B 6.80 5.00 3.30 1.44
C 6.96 5.86 4.78 3.60
D 7.90 7.08 6.28 5.46
E 7.19 6.80 6.44 6.05
TABLE II
Calculation of amylolytic activity
'Titration value of blank 7.07 7.07 7.07
Titration value of fractions 6.07 5.08 4.05
Increment in 20, 40, 60 minutes 1.0.0 1.99 3.02
Increment in each 20 minutes 1.00 0.995 1.007
Average 20-minute titration value = 1.00 cc.
1.00 X 2 X 0.890t X 0.55 X 3
= 2.94 mgm. maltose 1 cc. serum
1 hour
The titration values are those of Subject A in Table I.
t Correction factor for N/75 sodium thiosulfate used.
Modification of method for rapid determination. An
accurate rapid determination in serum of high amylase
activity may be carried out by making the following minor
changes in the method. Add 0.5 cc. of serum and 4.5 cc.
of water, instead of the quantities indicated above, and
limit the hydrolysis to two 10-minute periods. With this
modified method, the amylase value in serum of high
activity can be ascertained in less than one hour.
NORMALSUBJECTS
The individuals examined included patients who
had no evidence of organic disease, physicians and
other hospital workers. It will be seen that the
values, as shown in Table III, range between 0.5
TABLE III
Serum amylolytic activity in normal subjects
Mgm. maltose Number of








Average splitting 2.6 mgm.
and 5.5 mgm. (average 2.6 mgm.) of maltose
split by 1 cc. of serum in 1 hour. For this reason,
a unit of amylolytic activity for clinical purposes
was established as equal to 1 mgm. of maltose
formed by 1 cc. of serum in 1 hour under the con-




The blood of 56 diabetic patients was tested for
its amylase activity. The majority of the pa-
tients were ambulatory. All grades of diabetes,
with the exception of diabetic coma, and various
age groups, were included. The results disclose
the same range of amylolytic activity as was
found in the normal individuals. No relation-
ship to insulin therapy could be established.
TABLE IV
Serum amylolytic activity in diabetic patients







Total number of patients








PATIENTS WITH LIVER DISEASE
This series includes 5 cases of toxic hepatitis,
1 of acute yellow atrophy, 5 of Laennec's cirrhosis
(1 with intercurrent jaundice), 3 of cholelithiasis
presenting no symptoms of pancreatic involve-
ment, and 4 cases of obstructive icterus. The lat-
ter were of varied etiology: common duct stone,
xanthomatous biliary cirrhosis, and carcinoma of
the head of the pancreas. One case of congenital
hemolytic icterus and one of hepatomegaly in a
child with essential lipemia are also included in
this group. From the findings shown in Table
TABLE V




















Obstructive icterus (Xanthomatous biliary
cirrhosis)























V, it is seen that values similar to those in normal
individuals were obtained in all instances except
the one in which there was pancreatic involvement
due to carcinoma of the head of the pancreas.
PATIENT WITH GLYCOGENSTORAGEDISEASE
A value of 2.2 units was found in the blood of
a 3-day-old infant suffering from this disorder
of carbohydrate metabolism.5 Autopsy subse-
quently revealed typical findings of markedly in-
creased glycogen storage in the liver.
PATIENTS WITH VARIOUS CHILDHOODDISEASES
The results of blood amylase determinations in
7 children suffering from a variety of diseases are
given in Table VI. The values fell within the
range found in the normal subjects.
TABLE VI








PATIENTS WITH NON-DIABETIC PANCREATIC
DISEASE
Frequent determinations were made in 4 cases
of disease involving the excretory function of the
pancreas (Table VII). One of the cases is that
TABLE VII
Serum amylase in non-diabetic pancreatic disease
Patient A Patient B Patient C Patient D
Carcinoma of head Acute jaoreatic Acute,,areatic Acute pancreaticof pncreas a ed
Date Aln3'e Date AmnLae Dat AmyeaDete AmnylaseD^bunibtDe b uliib uDatb *b Dab units
April 27 39.98 May 4 24.04 May 17 55.29 May 25 49.20gay 2 43.71 May 5 12.70 May 18 9.07 May27 17.14
May 4 43.02 May 7 3.25 May 19 8.10 May28 8.23
May 7 36.15 May 12 3.00 May21 7.20 May30 1.60
May 25 40.60 May22 5.40
May 30 50.40 May23 5.90
May24 5.40
of the patient with carcinoma of the head of the
pancreas included in Table VI. The other 3 were
those of patients who entered the hospital with a
5 The blood from this patient was obtained through the
kindness of Dr. Elmer Barron and Dr. Francis Mac-
Donald of the Boston Floating Hospital.
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clinical picture characteristic of acute pancreati-
tis.6 The subsequent course and the clinical
investigations carried out made it possible to
establish the diagnosis of acute pancreatic edema,
secondary to cholelithiasis, in each of the cases.
A maintained increase of the blood amylase was
present in the patient with the carcinoma of the
head of the pancreas. The patients suffering
from acute pancreatic edema exhibited initial ele-
vations of considerable magnitude with a sub-
sequent return of the amylase activity to a normal
level within several days.
DISCUSSION
Non-diabetic pancreatic disease. The increased
blood amylase activity as observed in all of the 4
cases in this group is in accord with the long estab-
lished relationship between high blood amylase
values and disease of this type. The short dura-
tion of the increased activity in acute pancreati-
tides has also been well established clinically (14,
15) and experimentally (16), and the clinical
value of the blood amylase determination in these
conditions has been stressed (17). A maintained
increase of amylase activity as observed in the pa-
tient with carcinoma of the head of the pancreas
has not been reported previously. However, a
persistent increase in serum amylase activity has
been observed in dogs following permanent ex-
perimental closure of the pancreatic ducts (18).
Diseases of carbohydrate metabolism. The pa-
tients with diabetes, hepato-cellular liver disorders,
and the one patient with glycogen storage disease,
all exhibited normal blood amylase values. These
findings are in keeping with the fact that no role
has been found in the intermediary carbohydrate
metabolism for this enzyme, despite the recent
advancement of knowledge in this field. Recent
contributions (2, 3) demonstrate the presence in
liver, muscle, and other tissues, of a reversible
glycogen-glucose conversion mechanism which
depends on a specific phosphorylase-phosphatase
enzyme system. This work also supplies experi-
mental evidence that the mechanism is capable
by itself of fulfilling the body's requirements for
glucose obtained from glycogen stored in the liver,
6 The study of these patients was made possible through
the cooperation of Dr. Stephen Maddock, Director of the
Surgical Research Laboratories of the Boston City Hos-
pital.
and makes it appear highly improbable that amy-
lase participates in this essential phase of inter-
mediary carbohydrate metabolism (1).
Liver tissue possesses amylolytic activity, but
this activity probably results mainly from the
amylase contained in the hepatic blood and not in
the liver cells proper (19, 1, 8). However, re-
gardless of its source, there is no proof that the
amylase present in the liver has a function in
carbohydrate metabolism. Conversely, there are
reasons which make it doubtful that it has any
function in the liver. The activity of the enzyme
which is but slight in human blood is even less
marked in liver tissue. In duodenal juice, where
it plays a known role in the digestion of carbohy-
drates, the amylase is more than one thousand
times 7 as active as that of blood or liver. Fur-
thermore, amylase hydrolyzes starches to dextrins
and to maltose as an end product (20), and, in
physiological concentration, not at all or only in
small amounts to glucose (21). The presence of
the chief split products of amylolysis, maltose and
non-fermentable reducing substances, cannot be
demonstrated in liver tissue (8). Were maltose
to be formed as an intermediary product and
rapidly converted to the tissue utilizable glucose,
the aid of a highly active maltase would be re-
quired. The latter enzyme is not known to be
present in the human liver.
At present, therefore, there is no proof of the
participation of amylase in the intermediary car-
bohydrate metabolism. The recent work and the
other evidence mentioned militate against such an
assumption. In accord with this are the normal
blood amylase findings in diseases of carbohydrate
metabolism, as reported in this paper. These
findings may, therefore, be considered as clinical
evidence pointing in the same direction.
SUMMARYANDCONCLUSIONS
1. The blood amylolytic activity of 25 normal
patients was found to be between 0.5 and 5.5
mgm. (average 2.6 mgm.) of maltose per cc. of
serum per hour, with the method described.
2. A clinical unit of amylolytic activity was
established as equal to 1 mgm. of maltose formed




3. Normal blood amylase values were obtained
in 56 diabetics, 11 patients with hepato-cellular
liver disease, 8 with other types of liver disturb-
ance, and 1 with glycogen storage disease.
4. Markedly increased blood amylase activity
of transitory duration was observed in 3 patients
with acute pancreatic edema; similarly augmented
activity, but of a persistent nature, was found in
a patient suffering from a carcinoma of the head
of the pancreas.
5. The increased blood amylase activity en-
countered in the 4 patients with disease involving
the excretory function of the pancreas is in accord
with the clinical and experimental findings of
numerous other authors.
6. The normal blood amylase values in disease
of carbohydrate metabolism is offered as clinical
evidence of the non-participation of amylase in
the intermediary carbohydrate metabolism.
The author gratefully acknowledges the guidance given
him by Dr. S. J. Thannhauser in carrying out this study.
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